Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by LUAN TRUONG and TIMOTHY THOMPSON.
LUAN TRUONG
Connection Strength
0.723
TIMOTHY THOMPSON
  1. Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. Hum Pathol. 1993 Jan; 24(1):4-9.
    View in: PubMed
    Score: 0.110
  2. MMTV promoter-regulated caveolin-1 overexpression yields defective parenchymal epithelia in multiple exocrine organs of transgenic mice. Exp Mol Pathol. 2010 Aug; 89(1):9-19.
    View in: PubMed
    Score: 0.091
  3. Disruption of the caveolin-1 gene impairs renal calcium reabsorption and leads to hypercalciuria and urolithiasis. Am J Pathol. 2003 Apr; 162(4):1241-8.
    View in: PubMed
    Score: 0.056
  4. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res. 1999 Nov 15; 59(22):5719-23.
    View in: PubMed
    Score: 0.044
  5. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res. 1998 Aug; 4(8):1873-80.
    View in: PubMed
    Score: 0.040
  6. Apoptosis in renal cell carcinoma: detection by in situ end-labeling of fragmented DNA and correlation with other prognostic factors. Hum Pathol. 1996 Oct; 27(10):1012-7.
    View in: PubMed
    Score: 0.036
  7. Human cytomegalovirus is not implicated in benign prostatic hyperplasia: a study using immunohistochemistry and the polymerase chain reaction. J Urol. 1996 Aug; 156(2 Pt 1):542-5.
    View in: PubMed
    Score: 0.035
  8. Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: an immunohistochemical study. Clin Cancer Res. 1996 Apr; 2(4):635-40.
    View in: PubMed
    Score: 0.034
  9. Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin Cancer Res. 1996 Feb; 2(2):399-401.
    View in: PubMed
    Score: 0.034
  10. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest. 1995 Nov; 73(5):628-35.
    View in: PubMed
    Score: 0.033
  11. Mesenchymal-epithelial interactions and transforming growth factor-beta 1 expression during normal and abnormal prostatic growth. Microsc Res Tech. 1995 Mar 01; 30(4):333-41.
    View in: PubMed
    Score: 0.032
  12. The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate. Cancer. 1995 Jan 15; 75(2):522-9.
    View in: PubMed
    Score: 0.032
  13. Transforming growth factor-beta localization during mouse prostate morphogenesis and in prostatic growth abnormalities. World J Urol. 1995; 13(6):324-8.
    View in: PubMed
    Score: 0.032
  14. Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Hum Pathol. 1994 Aug; 25(8):797-801.
    View in: PubMed
    Score: 0.031
  15. Mesenchymal-epithelial interactions and transforming growth factor-beta expression during mouse prostate morphogenesis. Endocrinology. 1994 Mar; 134(3):1039-45.
    View in: PubMed
    Score: 0.030
  16. Transgenic models for the study of prostate cancer. Cancer. 1993 Feb 01; 71(3 Suppl):1165-71.
    View in: PubMed
    Score: 0.028
  17. Transforming growth factor beta 1 as a biomarker for prostate cancer. J Cell Biochem Suppl. 1992; 16H:54-61.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.